-
Third Clinical Trials Plenary Session delved into next-generation cellular therapies and immunotherapies
Omar Nadeem, MD, discussed results of the CAR-PRISM trial, which evaluated the use of ciltacabtagene autoleucel in patients with high-risk smoldering myeloma, an early, asymptomatic form of multiple myeloma.
-
Fourth Clinical Trials Plenary Session highlighted emerging developments in immunotherapy
Alberto Giovanni Leone, MD, shared results from cohort two of the single-arm, nonrandomized phase II INFINITY clinical trial assessing a combination treatment of tremelimumab and durvalumab.
-
Third Plenary Session examined the AI revolution across cancer labs and clinics
Suchi Saria, PhD, reviewed her work adapting AI to use in real-world health care settings—a proposition that, she said, necessarily requires a rigorous approach to build trust, considering the high-stakes environment of direct patient treatment.
-
Opening Plenary offered insights into therapeutic resistance and innovative approaches to cancer care
Charles L. Sawyers, MD, FAACR, explained that the progression from castration-sensitive to castration-resistant prostate cancer occurs, in part, through a lineage switch that converts prostate cancer cells from an adenocarcinoma cell state to a neuroendocrine state.
-
First Clinical Trials Plenary featured latest precision oncology therapies
Byoung Chul Cho, MD, presented updated results from a phase I/II clinical trial of the next-generation KRAS-G12C inhibitor elisrasib, which was designed for faster and stronger target engagement, to afford sustained inhibition, Cho explained.
-
Second Clinical Trials Plenary highlighted results of next-generation antibody-drug conjugates
Elizabeth K. Lee, MD, presented results from a phase I dose-escalation clinical trial testing a combination of the PARP inhibitor olaparib and the ADC DS-8201a, also known as trastuzumab deruxtecan.
Meet the 2026 NextGen Stars
